Explore the upcoming wave of biosimilars as major patents for drugs like Keytruda and Eylea expire. Learn about the differences from generics, market entry timelines, pricing impacts, and what this means for patient care.
Learn how the BPCIA and the 'patent dance' determine when biosimilars enter the U.S. market and why biologic patent protection differs from traditional generics.
Generic drugs save billions in healthcare costs worldwide. Discover the key trends shaping their future - from biosimilars and supply chain risks to India’s manufacturing boom and growing demand in emerging markets.